# Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

> **NCT00258700** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 478 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** Haemophilus influenzae type b- and meningococcal (vaccine)

## Key facts

- **NCT ID:** NCT00258700
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258700, "Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00258700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*